For decades, the conversation around plant-based medicine has been clouded by stigma, misinformation, and regulatory roadblocks. But that’s starting to change.
Stuart Marsh—Chief Commercial Officer of Cannim and a key contributor to the groundbreaking docuseries High Science®—joins me to discuss how science, patient stories, and a shifting cultural landscape are transforming the way we think about full-spectrum health.
We talk about the synergistic effect vs. the entourage effect, the economic case for new treatment approaches (spoiler: it could save the NHS £12-15K per patient, per year), and why word-of-mouth is outpacing government messaging when it comes to education.
Stuart explains how a 90-year-old in a retirement home might be more open to new therapies than your local regulator, the challenges of navigating strict advertising laws, and why the research-backed approach is the only way to move forward.
Also in this episode:
— The real meaning of full-spectrum medicine (and why it’s not just about THC or CBD percentages)
— Why big pharma is struggling to adapt to individualised, plant-based solutions.
— How the TGA’s heavy-handed regulations make it nearly impossible for providers to educate patients.
— The ripple effect of healthcare choices—on families, communities, and economies.
— My own experience of navigating a broken system as a patient with endometriosis—and what I wish I had known sooner.
It’s a conversation about science, policy, and the power of patient-led change—and it’s one you won’t want to miss.
